Genentech: Press Releases | Friday, Sep 13, 2024
WEBSep 13, 2024 · Ocrevus Zunovo™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs. South San Francisco, CA -- September 13, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ...
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
WEB6 days ago · The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for...
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB6 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Genentech: News Features | FDA Approves the First and Only …
WEBOn September 13, 2024, the FDA approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults.
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO …
WEBSep 13, 2024 · OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints.
FDA approves OCREVUS ZUNOVO™ as the first and only
WEB6 days ago · OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple...
FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis
WEBSep 13, 2024 · The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The approval marks the first and only twice yearly, health care professional-administrated subcutaneous (SC) injections for both forms of MS. 1
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat …
WEB6 days ago · OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional or HCP-administered approximately 10-minute subcutaneous injection approved for both these forms of MS.
Halozyme’s ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO…
WEB1 day ago · OCREVUS ZUNOVO™ offers a twice-a-year, 10-minute subcutaneous injection, administered by a healthcare professional. This represents a substantial improvement over the intravenous (IV) formulation, which requires a significantly longer infusion time. ... This news reinforces Halozyme’s strong position in the drug delivery space. The FDA’s ...
FDA Approves Ocrevus Zunovo™ | National MS Society
WEBSep 13, 2024 · Ocrevus Zunovo works in the body the same as Ocrevus. Its safety, efficacy, and side effect profile mirrors that of Ocrevus. The difference is in how the therapy is delivered: Ocrevus is given as an IV infusion which can take hours, while Ocrevus Zunovo is given as an HCP-administered SC injection over the course of …
- Some results have been removed
Skip to content